PERMA-FIX ENVIRONMENTAL SERVICES, INC. (NASDAQ:PESI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 –
On March 28, 2019, Perma-Fix Environmental Services, Inc. (the “Company”) issued a press release to report its preliminary financial results for the twelve months ended December 31, 2018. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information combined in this Item 2.02 of this Form 8-K and the Exhibits attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934 (as amended), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (as amended), except as shall be expressly set forth by specific reference in such filing.
| Section 9 – | Financial Statements and Exhibits |
| Item 9.01 – | Financial Statements and Exhibits |
| Exhibit Number | Description |
| 99.1 | Press release dated March 28, 2019 |
PERMA FIX ENVIRONMENTAL SERVICES INC Exhibit
EX-99.1 2 ex99-1.htm Perma-Fix Reports Preliminary Results for Fiscal 2018 Announces $17 million in new contract awards for 2019 ATLANTA – March 28,…
To view the full exhibit click here
About PERMA-FIX ENVIRONMENTAL SERVICES, INC. (NASDAQ:PESI)
Perma-Fix Environmental Services, Inc. is an environmental and environmental technology know-how company. It operates in three segments: The Treatment Segment (Treatment), the Services Segment (Services) and the Medical Segment (Medical). Treatment includes nuclear, low-level radioactive, mixed (waste containing both hazardous and low-level radioactive waste), hazardous and non-hazardous waste treatment, processing and disposal services primarily through approximately four licensed and permitted treatment and storage facilities held by its subsidiaries. Services include on-site waste management services to commercial and government customers, technical services and nuclear services. The Medical segment includes research and development (R&D) of a new medical isotope production technology by its Polish subsidiary, Perma-Fix Medical S.A. (PF Medical). Its Treatment and Services provide services to research institutions, commercial companies, public utilities and governmental agencies.
